Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory regulatory approval

Zealand Pharma Zeydovio EU CHMP Backing

Analysis based on 6 articles · First reported Sep 18, 2026 · Last updated Sep 18, 2026

Sentiment
25
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The CHMP positive opinion materially de-risks Zeydovio's European path to market, strengthening Zealand Pharma's revenue outlook and its leverage in ongoing global partnership negotiations, which should support the stock. Broader market impact is limited to the rare-disease and GLP-2 peptide space, with modest read-through for European biotech sentiment and no meaningful macro effect.

pharmaceuticals biotechnology healthcare

Zealand Pharma announced on September 18, 2026 that the European Union — European Medicines Agency's European Union — Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending marketing authorization for Zeydovio (glepaglutide) for the treatment of adults with short bowel syndrome (SBS). The recommendation was supported by data from the Phase 3 EASE-1 trial, in which twice-weekly glepaglutide reduced parenteral support requirements compared with placebo: 65.7% of treated patients achieved at least a 20% reduction in weekly parenteral support volume versus 38.9% on placebo, and five patients (14%) were completely weaned off parenteral support, while no placebo patients achieved this. Glepaglutide is a long-acting GLP-2 analogue administered twice weekly via a single-dose autoinjector. The International — European Commission will now review the opinion, with a final marketing authorization decision expected within approximately 67 days; if approved, the authorization would be valid across all European Union member states as well as Iceland, Liechtenstein, and Norway. Zealand Pharma said it is stepping up talks to find a global commercial partner responsible for the drug's launch in Europe and the United States, and is enrolling patients in the Phase 3 EASE-5 trial to support a US New Drug Application. The US United States — Food and Drug Administration has granted orphan drug designation to glepaglutide for short bowel syndrome. The positive opinion marks the first major advancement in SBS treatment in Europe in more than a decade, according to the company.

50 International — European Commission reviewing marketing authorization Zealand Pharma
45 Zealand Pharma reported trial results
stock
The Danish drugmaker is the central actor, gaining a CHMP positive opinion for Zeydovio in short bowel syndrome that de-risks European approval and boosts its partnering and commercial prospects.
Importance 100.0 Sentiment 55.0
govactor
The committee recommended marketing authorization for Zeydovio, the key regulatory action of this event.
Importance 70.0 Sentiment 10.0
govactor
Its CHMP committee issued the positive opinion that drives the event, reinforcing the agency's role as the gatekeeper for EU drug approvals.
Importance 60.0 Sentiment 10.0
govactor
It will review the CHMP opinion and is expected to issue a final marketing authorization decision within about 67 days.
Importance 45.0 Sentiment 5.0
govactor
The US regulator has granted orphan drug designation to glepaglutide and will assess a future New Drug Application supported by the EASE-5 trial.
Importance 30.0 Sentiment 5.0
cnt
Target market for Zealand Pharma's planned US New Drug Application, supported by the ongoing Phase 3 EASE-5 trial.
Importance 25.0 Sentiment 5.0
alliance
A positive International — European Commission decision would make the marketing authorization valid across all EU member states.
Importance 25.0 Sentiment 5.0
cnt
Home country of Zealand Pharma, gaining reflected prestige from a Danish biotech's EU regulatory milestone.
Importance 20.0 Sentiment 10.0
cnt
Would be covered by the marketing authorization if the International — European Commission grants approval.
Importance 5.0 Sentiment 5.0
cnt
Would be covered by the marketing authorization if the International — European Commission grants approval.
Importance 5.0 Sentiment 5.0
cnt
Would be covered by the marketing authorization if the International — European Commission grants approval.
Importance 5.0 Sentiment 5.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.